Abstract
Broad-spectrum antifungal prophylaxis is currently considered the standard of care for adults with de novo AML for the prevention of invasive fungal infections (IFIs), especially invasive pulmonary aspergillosis (IPA). Because fluconazole has been used in our center as anti-yeast prophylaxis, we sought to analyze in detail the incidence of IFIs over a 17-year period, as well as their impact on outcome. A standardized protocol of patient management, including serum galactomannan screening and thoracic CT-guided diagnostic-driven antifungal therapy, was used in all patients. A total of 214 consecutive adults with de novo AML who were treated in 3 CETLAM (Grupo Cooperativo para el Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias) protocols from 2002 to 2018 were included. The 90-day incidence of any IFI (including possible cases) was 11% (95% CI 4–15%), most cases occurred during induction chemotherapy (8%, 95% CI 4–12%), and most cases were probable/proven IPA (8%, 95% CI 3–13%). Developing an IFI during induction and consolidation had no impact on 1-year survival. A case–control study with 23 cases of IPA and 69 controls identified induction/re-induction chemotherapy, chronic pulmonary disease and age > 60 years/poor baseline performance status as potential pretreatment risk factors. The current study proves that inpatient induction and consolidation chemotherapy for de novo AML can be given in areas with “a priori” high-burden of airborne molds with fluconazole prophylaxis, while the selective use of anti-mold prophylaxis in patients at very high risk may further reduce the incidence of IFI in this specific clinical scenario.
Similar content being viewed by others
References
Pagano L, Busca A, Candoni A, Cattaneo C, Cesaro S, Fanci R, Nadali G, Potenza L, Russo D, Tumbarello M, Nosari A, Aversa F. Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations. Blood Rev. 2017;31:17–29.
Martino R, Subira M. Invasive fungal infections in hematology: new trends. Ann Hematol. 2002;81:233–43.
Pagano L, Caira M, Candoni A, Aversa F, Castagnola C, Caramatti C, Cattaneo C, Delia M, De Paolis MR, Di BR, Di CL, Fanci R, Garzia M, Martino B, Melillo L, Mitra ME, Nadali G, Nosari A, Picardi M, Potenza L, Salutari P, Trecarichi EM, Tumbarello M, Verga L, Vianelli N, Busca A. Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry. Clin Infect Dis. 2012;55:1515–21.
Del Principe MI, Dragonetti G, Verga L, Candoni A, Marchesi F, Cattaneo C, Delia M, Potenza L, Farina F, Ballanti S, Decembrino N, Castagnola C, Nadali G, Fanci R, Orciulo E, Veggia B, Offidani M, Melillo L, Manetta S, Tumbarello M, Venditti A, Busca A, Aversa F, Pagano L. ‘Real-life’ analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study. J Antimicrob Chemother. 2019;74:1062–8.
Maertens JA, Girmenia C, Bruggemann RJ, Duarte RF, Kibbler CC, Ljungman P, Racil Z, Ribaud P, Slavin MA, Cornely OA, Peter DJ, Cordonnier C. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. J Antimicrob Chemother. 2018;73:3221–30.
Donnelly JP, Cordonnier C, Cuenca-Estrella M et al. A European prospective invasive mould disease audit. In: Twenty-fourth European Congress of Clinical Microbiology and Infectious Diseases, 10–13 May 2014, Barcelona, Spain. Abstract P0028a.
Barnes R, Rogers T, Maertens J. Defining standards of CARE for invasive fungal diseases in adult haematology patients: antifungal prophylaxis versus treatment. J Antimicrob Chemother. 2019;74:ii21–6.
Busca A, Pagano L. Prophylaxis for aspergillosis in patients with haematological malignancies: pros and cons. Expert Rev Anti Infect Ther. 2018;16:531–42.
Garcia-Vidal C, Royo-Cebrecos C, Peghin M, Moreno A, Ruiz-Camps I, Cervera C, Belmonte J, Gudiol C, Labori M, Rosello E, de la Bellacasa JP, Ayats J, Carratala J. Environmental variables associated with an increased risk of invasive aspergillosis. Clin Microbiol Infect. 2014;20:O939–45.
Sanchez-Ortega I, Patino B, Arnan M, Peralta T, Parody R, Gudiol C, Encuentra M, de Fernandez SA, Duarte RF. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole vs itraconazole in allogeneic blood and marrow transplantation. Bone Marrow Transplant. 2011;46:733–9.
Rodriguez-Veiga R, Montesinos P, Boluda B, Lorenzo I, Martinez-Cuadron D, Salavert M, Peman J, Calvillo P, Cano I, Acuna E, Villalba A, Pinana JL, Sanz J, Solves P, Senent L, Vicente A, Sempere A, Cervera J, Barragan E, Jarque I, Torres A, Sanz MA, Sanz GF. Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis. Ann Hematol. 2019;98:2081–8.
Tormo M, Perez-Martinez A, Calabuig M, Hernandez-Boluda JC, Amat P, Navarro D, Solano C. Primary prophylaxis of invasive fungal infections with posaconazole or itraconazole in patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing intensive cytotoxic chemotherapy: a real-world comparison. Mycoses. 2018;61:206–12.
Martino R, Pinana JL, Parody R, Valcarcel D, Sureda A, Brunet S, Briones J, Delgado J, Sanchez F, Rabella N, Sierra J. Lower respiratory tract respiratory virus infections increase the risk of invasive aspergillosis after a reduced-intensity allogeneic hematopoietic SCT. Bone Marrow Transplant. 2009;44:749–56.
Parody R, Martino R, de la CR, Garcia-Noblejas A, Esquirol A, Garcia-Cadenas I, Villaescusa T, Caballero D, Rovira M, Fernandez-Aviles F, Marquez-Malaver FJ, Espigado I, Castilla-Llorente C, Heras I, Cabero MA, Cabrera JR, Barba P, Valcarcel D, Sanchez-Ortega I, Duarte RF, Serrano D, Carretero F, Vazquez L. Fungal and viral infections after allogeneic hematopoietic transplantation from unrelated donors in adults: improving outcomes over time. Bone Marrow Transplant. 2015;50:274–81.
Martino R, Kerguelen A, Valcarcel D, Sureda A, Fachini L, Pinana JL, Briones J, Delgado J, Brunet S, Sierra J. Reduction of infection-related mortality after allogeneic PBSCT from HLA-identical siblings: longitudinal analysis from 1994 to 2008 at a single institution. Bone Marrow Transplant. 2011;46:690–701.
Hidalgo A, Parody R, Martino R, Sanchez F, Franquet T, Gimenez A, Blancas C. Correlation between high-resolution computed tomography and galactomannan antigenemia in adult hematologic patients at risk for invasive aspergillosis. Eur J Radiol. 2009;71:55–60.
Ramila E, Sureda A, Martino R, Santamaria A, Franquet T, Puzo C, Montesinos J, Perea G, Sierra J. Bronchoscopy guided by high-resolution computed tomography for the diagnosis of pulmonary infections in patients with hematologic malignancies and normal plain chest X-ray. Haematologica. 2000;85:961–6.
Martino R, Viscoli C. Empirical antifungal therapy in patients with neutropenia and persistent or recurrent fever of unknown origin. Br J Haematol. 2006;132:138–54.
Subira M, Martino R, Gomez L, Marti JM, Estany C, Sierra J. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies–a randomized, controlled trial. Eur J Haematol. 2004;72:342–7.
Martino R, Subira M, Sureda A, Sierra J. Amphotericin B lipid complex at 3 mg/kg/day for treatment of invasive fungal infections in adults with haematological malignancies. J Antimicrob Chemother. 1999;44:569–72.
Martino R, Cortes M, Subira M, Parody R, Moreno E, Sierra J. Efficacy and toxicity of intermediate-dose amphotericin B lipid complex as a primary or salvage treatment of fungal infections in patients with hematological malignancies. Leuk Lymphoma. 2005;46:1429–35.
Viscoli C, Herbrecht R, Akan H, Baila L, Sonet A, Gallamini A, Giagounidis A, Marchetti O, Martino R, Meert L, Paesmans M, Ameye L, Shivaprakash M, Ullmann AJ, Maertens J. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J Antimicrob Chemother. 2009;64:1274–81.
De PB, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Munoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813–21.
Lanternier F, Seidel D, Pagano L, Styczynski J, Mikulska M, Pulcini C, Maertens J, Munoz P, Garcia C, Rijnders B, Arendrup MC, Sabino R, Verissimo C, Gaustad P, Klimko N, rikan-Akdagli S, Arsic V, Barac A, Skiada A, Klingspor L, Herbrecht R, Donnelly P, Cornely OA, Lass-Florl C, Lortholary O. Invasive Pulmonary Aspergillosis treatment duration in haematology patients in Europe: an EFISG, IDWP-EBMT, EORTC-IDG, SEIFEM survey. Mycoses. 2020;63:420–9.
Valcarcel D, Montesinos P, Sanchez-Ortega I, Brunet S, Esteve J, Martinez-Cuadron D, Ribera JM, Tormo M, Bueno J, Duarte R, Llorente A, Torres JP, Guardia R, Sanz MA, Sierra AJ. A scoring system to predict the risk of death during induction with anthracycline plus cytarabine-based chemotherapy in patients with de novo acute myeloid leukemia. Cancer. 2012;118:410–7.
Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, Clancy CJ, Wingard JR, Lockhart SR, Groll AH, Sorrell TC, Bassetti M, Akan H, Alexander BD, Andes D, Azoulay E, Bialek R, Bradsher RW, Bretagne S, Calandra T, Caliendo AM, Castagnola E, Cruciani M, Cuenca-Estrella M, Decker CF, Desai SR, Fisher B, Harrison T, Heussel CP, Jensen HE, Kibbler CC, Kontoyiannis DP, Kullberg BJ, Lagrou K, Lamoth F, Lehrnbecher T, Loeffler J, Lortholary O, Maertens J, Marchetti O, Marr KA, Masur H, Meis JF, Morrisey CO, Nucci M, Ostrosky-Zeichner L, Pagano L, Patterson TF, Perfect JR, Racil Z, Roilides E, Ruhnke M, Prokop CS, Shoham S, Slavin MA, Stevens DA, Thompson GR, Vazquez JA, Viscoli C, Walsh TJ, Warris A, Wheat LJ, White PL, Zaoutis TE, Pappas PG. Revision and update of the consensus definitions of invasive fungal ddisease from the European organization for research and treatment of cancer and the Mycoses study group education and research consortium. Clin Infect Dis. 2019. https://doi.org/10.1093/cid/ciz1008.
Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, Ouellette M, Outterson K, Patel J, Cavaleri M, Cox EM, Houchens CR, Grayson ML, Hansen P, Singh N, Theuretzbacher U, Magrini N. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18:318–27.
Averbuch D, Tridello G, Hoek J, Mikulska M, Akan H, Yanez San SL, Pabst T, Ozcelik T, Klyasova G, Donnini I, Wu D, Gulbas Z, Zuckerman T, de Botelho SA, Beguin Y, Xhaard A, Bachy E, Ljungman P, de la CR, Rascon J, Ruiz CI, Vitek A, Patriarca F, Cudillo L, Vrhovac R, Shaw PJ, Wolfs T, O’Brien T, Avni B, Silling G, Al SF, Graphakos S, Sankelo M, Sengeloev H, Pillai S, Matthes S, Melanthiou F, Iacobelli S, Styczynski J, Engelhard D, Cesaro S. Antimicrobial resistance in gram-negative rods causing bacteremia in hematopoietic stem cell transplant recipients: intercontinental prospective study of the infectious diseases working party of the European Bone Marrow Transplantation Group. Clin Infect Dis. 2017;65:1819–28.
Parody R, Martino R, Sanchez F, Subira M, Hidalgo A, Sierra J. Predicting survival in adults with invasive aspergillosis during therapy for hematological malignancies or after hematopoietic stem cell transplantation: Single-center analysis and validation of the Seattle, French, and Strasbourg prognostic indexes. Am J Hematol. 2009;84:571–8.
Subira M, Martino R, Franquet T, Puzo C, Altes A, Sureda A, Brunet S, Sierra J. Invasive pulmonary aspergillosis in patients with hematologic malignancies: survival and prognostic factors. Haematologica. 2002;87:528–34.
Dragonetti G, Criscuolo M, Fianchi L, Pagano L. Invasive aspergillosis in acute myeloid leukemia: are we making progress in reducing mortality? Med Mycol. 2017;55:82–6.
Pagano L, Caira M, Candoni A, Offidani M, Martino B, Specchia G, Pastore D, Stanzani M, Cattaneo C, Fanci R, Caramatti C, Rossini F, Luppi M, Potenza L, Ferrara F, Mitra ME, Fadda RM, Invernizzi R, Aloisi T, Picardi M, Bonini A, Vacca A, Chierichini A, Melillo L, de WC, Fianchi L, Riva M, Leone G, Aversa F, Nosari A. Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica. 2010;95:644–50.
Hahn-Ast C, Felder L, Mayer K, Muckter S, Ruhnke M, Hein R, Hellmich M, Schwab K, Rachow T, Brossart P, von Lilienfeld-Toal M. Outcome of empirical or targeted antifungal therapy after antifungal prophylaxis in febrile neutropenia. Ann Hematol. 2016;95:1001–9.
Duarte RF, Sanchez-Ortega I, Cuesta I, Arnan M, Patino B, de Fernandez SA, Gudiol C, Ayats J, Cuenca-Estrella M. Serum galactomannan-based early detection of invasive aspergillosis in hematology patients receiving effective antimold prophylaxis. Clin Infect Dis. 2014;59:1696–702.
Michallet M, Benet T, Sobh M, Kraghel S, El HM, Cannas G, Nicolini FE, Labussiere H, Ducastelle S, Barraco F, Thomas X, Chelghoum Y, Nicolle MC, Bienvenu AL, Persat F, De MF, Picot S, Vanhems P. Invasive aspergillosis: an important risk factor on the short- and long-term survival of acute myeloid leukemia (AML) patients. Eur J Clin Microbiol Infect Dis. 2012;31:991–7.
Tang JL, Kung HC, Lei WC, Yao M, Wu UI, Hsu SC, Lin CT, Li CC, Wu SJ, Hou HA, Chou WC, Huang SY, Tsay W, Chen YC, Chen YC, Chang SC, Ko BS, Tien HF. High incidences of invasive fungal infections in acute myeloid leukemia patients receiving induction chemotherapy without systemic antifungal prophylaxis: a Prospective Observational Study in Taiwan. PLoS ONE. 2015;10:e0128410.
Wang L, Hu J, Sun Y, Huang H, Chen J, Li J, Ma J, Li J, Liang Y, Wang J, Li Y, Yu K, Hu J, Jin J, Wang C, Wu D, Xiao Y, Huang X. Does high-dose cytarabine cause more fungal infection in patients with acute myeloid leukemia undergoing consolidation therapy: a multicenter, prospective, observational study in China. Medicine (Baltimore). 2016;95:e2560.
Caira M, Candoni A, Verga L, Busca A, Delia M, Nosari A, Caramatti C, Castagnola C, Cattaneo C, Fanci R, Chierichini A, Melillo L, Mitra ME, Picardi M, Potenza L, Salutari P, Vianelli N, Facchini L, Cesarini M, De Paolis MR, Di BR, Farina F, Venditti A, Ferrari A, Garzia M, Gasbarrino C, Invernizzi R, Lessi F, Manna A, Martino B, Nadali G, Offidani M, Paris L, Pavone V, Rossi G, Spadea A, Specchia G, Trecarichi EM, Vacca A, Cesaro S, Perriello V, Aversa F, Tumbarello M, Pagano L. Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study). Haematologica. 2015;100:284–92.
Wirmann L, Ross B, Reimann O, Steinmann J, Rath PM. Airborne Aspergillus fumigatus spore concentration during demolition of a building on a hospital site, and patient risk determination for invasive aspergillosis including azole resistance. J Hosp Infect. 2018;100:e91–7.
Perea G, Lasa A, Aventin A, Domingo A, Villamor N, Queipo de Llano MP, Llorente A, Junca J, Palacios C, Fernandez C, Gallart M, Font L, Tormo M, Florensa L, Bargay J, Marti JM, Vivancos P, Torres P, Berlanga JJ, Badell I, Brunet S, Sierra J, Nomdedeu JF. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]. Leukemia. 2006;20:87–94.
A. Garrido, S. Brunet, M. Calabuig, M. Diaz-Beyá, S. Vives, M. Cervera, H. Pomares, R. Guardia, O. Salamero, MP. Queipo de Llano, J. Bargay, A. Sampol, C. Pedro, A. Garcia, JM. Marti-Tutusaus, I. Heras, P. Torres, Ll. Font, J. Gonzalez, D. Hernandez, M. Hoyos, D. Gallardo, M. Arnan, L. Escoda, JM. Ribera, J. Esteve, M. Tormo, JF. Nomdedeu, J. Sierra final results of the CETLAM LAM-2003 trial for the treatment of primary AML up to the age of 70. Haematologica 2017; 102 (Supplement_2):322 (S790).
Sierra J, Garrido A, Diaz Beya M, Hoyos M, Calabuig M, Vives S, Arnan M, et al. Final results of the AML12 trial of the Spanish CETLAM Group in adults with acute myeloid leukemia (AML) up to the age of 70 years: risk adapted post-remission allocation based on genetic data and minimal residual disease. Blood. 2019;134(Supplement_1):289. https://doi.org/10.1182/blood-2019-128682.
Bose P, McCue D, Wurster S, Wiederhold NP, Konopleva M, Kadia TM, et al. Isavuconazole as primary anti-fungal prophylaxis in patients with acute myeloid leukemia or myelodysplastic syndrome: an open-label, prospective. Phase II study. Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa358.
Stern A, Su Y, Lee YJ, Seo S, Shaffer B, Tamariet R, al. A single-center, open-label trial of isavuconazole prophylaxis against invasive fungal infection in patients undergoing allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2020;26:1195–202.
Fontana L, Perlin DS, Zhao Y, Noble BN, Lewis JS, Strasfeld L, Hakki M. Isavuconazole prophylaxis in patients with hematologic malignancies and hematopoietic cell transplant recipients. Clin Infect Dis. 2020;70:723–30.
Acknowledgements
This study was performed in the setting of the CETLAM cooperative group (Grupo Cooperativo para el Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias, protocols CETLAM-99, CETLAM-2003 and CETLAM-2012), in part with grants C03/010 and 603/008 from the Instituto de Salud Carlos III, and two grants from Fundació d’Investigació Sant Pau and Fundació “La Caixa” (Barcelona, Spain).
Funding
This study was performed in the setting of the CETLAM cooperative group (Grupo Cooperativo para el Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias, protocols CETLAM-99, CETLAM-2003 and CETLAM-2012), in part with grants C03/010 and 603/008 from the Instituto de Salud Carlos III, and two grants from Fundació d’Investigació Sant Pau and Fundació “La Caixa” (Barcelona, Spain).
Author information
Authors and Affiliations
Contributions
RM was involved in conception and execution of the research reported in the paper, the integrity and analysis of the data, inpatient care and writing the various versions of the manuscript. In addition, he also had the task of data management and statistical analyses. AG and MS collaborated in patient care, performed most data management, contributed to the conception and execution of the research reported in the paper, and participated in writing or interpreting relevant parts of the manuscript. All other co-authors contributed to the conception and execution of the research reported in the paper, collaborated in patient care and participated in writing or interpreting relevant parts of the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
None of the authors reports any conflict of interest for this manuscript.
Ethics Approval
Due to the retrospective nature of the study, ethical approval was waived by our center’s Ethical Committee. However, all patients signed an informed consent for each of the 3 CETLAM protocols in which they were included, which complied with national ethical regulations as well as the principles laid in the 1964 Declaration of Helsinki.
Consent for Publication
All authors agree to the submission of the manuscript in its actual format.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Handling Editor: Sanjay Haresh Chotirmall.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Martino, R., Garrido, A., Santaliestra, M. et al. Low Rate of Invasive Fungal Infections During Induction and Consolidation Chemotherapy for Adults with De Novo Acute Myeloid Leukemia Without Anti-mold Prophylaxis: Single-Center 2002–2018 Empirical/Pre-emptive Approach. Mycopathologia 185, 639–652 (2020). https://doi.org/10.1007/s11046-020-00461-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11046-020-00461-w